Literature DB >> 2098915

Quinine resistant falciparum malaria treated with mefloquine.

T Harinasuta1, D Bunnag, R Lasserre.   

Abstract

Twenty eight adult male patients with acute uncomplicated falciparum malaria which showed RI or RII responses to quinine sulfate at the dosage of 600 mg 8 hourly for 7, 10 or 14 days were treated with a single dose of mefloquine (Lariam); 25 patients received 1000 mg, 2 received 750 mg and 1 received 500 mg. The initial response was good; there was no RII or RIII response. Three patients were lost to followup. Of 25 patients who stayed in the Bangkok Hospital for Tropical Diseases where there was no malaria transmission for 28-65 days, only one patient in the 1000 mg group had recrudescence on day 21. The cure rate was 96%. Our prospective study suggests that mefloquine was effective in the treatment of quinine resistant falciparum malaria and the risk of cross-resistance between quinine and mefloquine in P. falciparum in vivo is very low.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2098915

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  7 in total

1.  Differential association of Plasmodium falciparum Na+/H+ exchanger polymorphism and quinine responses in field- and culture-adapted isolates of Plasmodium falciparum.

Authors:  Stéphane Pelleau; Lionel Bertaux; Sébastien Briolant; Michael T Ferdig; Véronique Sinou; Bruno Pradines; Daniel Parzy; Ronan Jambou
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 2.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

3.  Comparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malaria.

Authors:  J Karbwang; K Na-Bangchang; A Thanavibul; D Bunnag; T Chongsuphajaisiddhi; T Harinasuta
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

4.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

5.  Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine.

Authors:  Maud Henry; Sébastien Briolant; Agnès Zettor; Stéphane Pelleau; Meili Baragatti; Eric Baret; Joel Mosnier; Rémy Amalvict; Thierry Fusai; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

6.  In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) gene: the absence of association in clinical isolates from the Republic of Congo.

Authors:  Sébastien Briolant; Stéphane Pelleau; Hervé Bogreau; Philippe Hovette; Agnès Zettor; Jacky Castello; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2011-02-11       Impact factor: 2.979

7.  In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na+/H+ exchanger transporter (Pfnhe-1) gene in 393 isolates from Dakar, Senegal.

Authors:  Aurélie Pascual; Bécaye Fall; Nathalie Wurtz; Mansour Fall; Cheikhou Camara; Aminata Nakoulima; Eric Baret; Bakary Diatta; Khadidiatou Ba Fall; Pape Saliou Mbaye; Yaya Diémé; Raymond Bercion; Hervé Bogreau; Sébastien Briolant; Christophe Rogier; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2013-06-07       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.